List view / Grid view
7 April 2015 | By Victoria White
Bristol-Myers Squibb get exclusive access to uniQure’s gene therapy technology platform for multiple targets in cardiovascular diseases...
30 March 2015 | By Victoria White
A new trial of the drug Abatacept could bring hope to the millions of Britons who are likely to one day suffer from rheumatoid arthritis...
24 March 2015 | By Victoria White
Bristol-Myers Squibb acquires license from Novo Nordisk for a discovery biologics research programme focused on modulating the innate immune system...
4 March 2015 | By Bristol-Myers Squibb Company
Bavarian Nordic to receive up to $975 million, inclusive of $60 million upfront and potential exercise payment; potential development, regulatory and commercialization milestone payments; additional tiered double-digit royalties on future sales...
26 February 2015 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced data supporting the clinical development of BMS-955176, an investigational component designed to prevent the maturation of HIV-1...
10 December 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company and Pfizer Inc. announced results of the first human study evaluating the reversal of the anticoagulant effect of Eliquis (apixaban) by 4-factor prothrombin complex concentrates (PCCs) in healthy subjects...
24 November 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb and Five Prime Therapeutics have announced exclusive clinical collaboration to evaluate the combination of investigational immunotherapies Opdivo (nivolumab) and FPA008 in six tumor types...
13 November 2014 | By Bristol-Myers Squibb
The Partnering for Cure faculty of experts announced the four recipients of awards for research proposals that will help to provide insights into the pathophysiology of viral diseases and the potential development of cure strategies in HIV, hepatitis B (HBV) and hepatitis C (HCV)...
9 October 2014 | By Novartis
Novartis announced that it has entered into a clinical collaboration with Bristol-Myers Squibb Company to evaluate the safety, tolerability and preliminary efficacy of three molecularly targeted compounds in combination with Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor, Opdivo® (nivolumab)...
8 October 2014 | By Bristol-Myers Squibb Company
Studies will evaluate Bristol-Myers Squibb’s investigational PD-1 immune checkpoint inhibitor Opdivo (nivolumab) in combination with Novartis’ Zykadia (ceritinib), INC280 and EGF816...
3 October 2014 | By Allied-Bristol Life Sciences
Allied-Bristol Life Sciences today announced that Satish Jindal, Ph.D., formerly Vice President of R&D within Bristol-Myers, has been appointed to lead the company’s efforts to identify and foster development of biopharmaceutical innovations from top U.S. university research institutions...
4 August 2014 | By Bristol-Myers Squibb Company
Allied Minds and Bristol-Myers Squibb Company announced the formation of Allied-Bristol Life Sciences LLC, a new jointly owned enterprise created to identify and foster research and pre-clinical development of biopharmaceutical innovations from leading university research institutions across the U.S...
25 June 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced that a randomized blinded comparative Phase 3 study evaluating nivolumab versus dacarbazine in patients with previously untreated BRAF wild-type advanced melanoma...
11 June 2014 | By Bristol-Myers Squibb Company
Bristol-Myers Squibb Company announced its first release of new data from a Phase IIIb RA trial showing that the T-cell co-stimulation modulator, Orencia...
3 June 2014 | By Bristol-Myers Squibb
Bristol-Myers Squibb Company announced follow up results from Study -004, a multi-arm Phase 1b dose-ranging trial evaluating the safety and activity of the combination regimen of nivolumab...
